CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: The combination of venetolcax (a BCL-2 inhibitor) and TKI synergistically promotes the apoptosis of CD34+ CML cells by targeting mitochondrial oxidative phosphorylation [49].